Saved local watchlist · Deprioritization mentions · sorted by registry update date
Candidate queue
877 active trial–asset records · showing latest 25 · no composite ranking
An ingestion window is pending. Refresh resumes the next page.
| Asset / trial | Sponsor / phase | Status / stopping reason | Independent scores | Source |
|---|---|---|---|---|
| adalimumab (up to 9 months exposure)NCT00233558 | AbbottPHASE4 | TERMINATED Study terminated due to low subject enrollment. Safety results consistent with product label. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-04-24 |
| Weekly Taxotere with weekly carboplatinNCT00247988 | University of SaskatchewanPHASE2 | TERMINATED Regulatory issues(trial temporarily suspended December 28, 2005. Permanently suspended January 19, 2007. Institutional Reveiw Board informed April 18, 2007 | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-04-24 |
| Glargine and insulin aspart or lisproNCT00464854 | Assaf-Harofeh Medical CenterNA | TERMINATED The study was started before the official request for protocol registration | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-04-24 |
| peg interferon plus ribavirinNCT00296972 | University Health Network, TorontoPHASE3 | TERMINATED not funded | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-04-23 |
| docetaxel and capecitabineNCT00225056 | Oncology Specialties, AlabamaPHASE2 | TERMINATED Terminated due to lack of accrual | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-04-20 |
| FK506 0.06% (eye drops)NCT00463723 | University Hospital FreiburgPHASE2, PHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2007-04-20 |
| FurosemideNCT00298454 | Frisius Medisch CentrumPHASE3 | TERMINATED Number included has been reached | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-04-19 |
| Lidocaine infusion plus ketamine injectionNCT00229567 | University of SaskatchewanNA | TERMINATED insufficient numbers of eligible patients as laparscopic surgery increased and open surgery decreased. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-04-19 |
| IrinotecanNCT00106262 | Women and Infants Hospital of Rhode IslandPHASE2 | TERMINATED Lack of accrual | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-04-18 |
| Velcade (bortezomib)NCT00106262 | Women and Infants Hospital of Rhode IslandPHASE2 | TERMINATED Lack of accrual | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-04-18 |
| curcumin; coenzyme q10NCT00247026 | Hadassah Medical OrganizationPHASE1, PHASE2 | WITHDRAWN No funding | ScienceUnknown SafetyUnknown Strategic-abandonment likelihood75 Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-04-11 |
| Morphine sulphateNCT00270322 | Rambam Health Care CampusPHASE4 | TERMINATED We believe regional anesth better for TKR,90% patients got epidural. Last year we started spinal morphine one shot, and found it very promissing. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-04-11 |
| Marcaine 0.166% + Fentanyl 3.33 mcg/mlNCT00270322 | Rambam Health Care CampusPHASE4 | TERMINATED We believe regional anesth better for TKR,90% patients got epidural. Last year we started spinal morphine one shot, and found it very promissing. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-04-11 |
| terlipressinNCT00287664 | Hospital Clinic of BarcelonaPHASE4 | SUSPENDED because in a preliminary analysis we would need 1000 patients per group to achieve significative differences in the main end point. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-04-11 |
| Oxaliplatin (Eloxatin)NCT00316433 | Swedish Medical CenterPHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-04-05 |
| Irinotecan (CPT-11)NCT00316433 | Swedish Medical CenterPHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-04-05 |
| Smoked CannabisNCT00260741 | Center for Medicinal Cannabis ResearchPHASE1, PHASE2 | TERMINATED Discontinued due to non-enrollment. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-04-04 |
| rhIGF-1/rhIGFBP-3NCT00351221 | Insmed IncorporatedPHASE2 | TERMINATED Terminated due to a patent legal settlement | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-03-30 |
| PD-217,014NCT00159640 | PfizerPHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-03-28 |
| TTI-237NCT00195325 | Wyeth is now a wholly owned subsidiary of PfizerPHASE1 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-03-26 |
| TTI-237NCT00195247 | Wyeth is now a wholly owned subsidiary of PfizerPHASE1 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-03-26 |
| Garlic Oil MacerateNCT00275405 | Albany Medical CollegePHASE4 | SUSPENDED Results inconclusive | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-03-20 |
| Tenofovir Disoproxil Fumarate 300 mg dailyNCT00111150 | Centers for Disease Control and PreventionPHASE2, PHASE3 | TERMINATED Consenting participants entered tenofovir/emtricitabine oral prophylaxis trial | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2007-03-19 |
| Soluble beta-1,3/1,6-glucanNCT00283426 | Biotec Pharmacon ASAPHASE1 | TERMINATED Slow patient recruitment | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-03-19 |
| LXR-623NCT00379860 | Wyeth is now a wholly owned subsidiary of PfizerPHASE1 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2007-03-09 |
Recent ingestion runs
| Source | Studies seen | Candidate writes | Status / finished |
|---|---|---|---|
| pubmed | 240 | 100 | finished2026-09-21T03:58:28.397783+00:00 |
| pubmed | 0 | 0 | failed2026-09-21T03:48:59.232056+00:00 |
| sec | 0 | 0 | finished2026-09-21T03:48:59.212906+00:00 |
| ClinicalTrials.gov | 300 | 258 | partial2026-09-21T03:48:59.189357+00:00 |
| ClinicalTrials.gov | 300 | 305 | Legacy run2026-09-21T03:45:47.341408+00:00 |
| ClinicalTrials.gov | 300 | 348 | Legacy run2026-09-21T03:38:48.082427+00:00 |